Suppliers / Pharmazell (India)

Pharmazell (India)

India 3 duplicate records merged Updated 9 July 2026

Pharmazell (India) is an API manufacturer based in India. It holds one active US drug master file. Its GMP standing is certified by EMA, US FDA and CDSCO (India). Its most recent recorded inspection, by US FDA, closed on 9 May 2025 as VAI. Customs aggregates show $9.4M of exports covering 86 molecules to 20 destinations in 2025.

1
active US DMFs
0
valid CEPs
5
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 9 May 2025 VAI US FDA
  • 7 February 2025 VAI US FDA
  • 20 February 2020 VAI US FDA
  • 14 December 2018 NAI US FDA
  • 11 August 2017 VAI US FDA
  • 6 February 2015 VAI US FDA
  • 20 June 2014 VAI US FDA
  • 10 November 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chennai, India 3003602532
Chennai-600 045, India Not on file
Anakapalli, India 3008248967
Visakhapatnam, India Not on file
mepz tambaram chennai 600045, India Not on file

What they file, and where

Molecule Regulators Docs
Celecoxib US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 2
US FDA None 2
CDSCO (India) None 2

Scale

Year Revenue Exports Destinations
2025 Not reported $9.4M 20
2022 Not reported $1.0M 9

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Pharmazell (India) comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 9 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts